GSK Arexvy Expands to At-Risk Adults 18-49; Novartis Cosentyx Pediatric HS Approval

GSK just cracked open a new RSV market — FDA clears Arexvy for at-risk adults as young as 18, and the competitive implications are significant.

Add Novartis locking down the only IL-17A approval for pediatric hidradenitis suppurativa, plus Pfizer quietly killing its small biotech support unit. Friday the 13th is treating pharma very well.

Welcome to The Pharma Closeout for Friday, March 13th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's close out the week.

GSK just got something vaccine makers almost never get — a meaningful label expansion into a younger patient population. The FDA cleared Arexvy for at-risk adults ages 18 to 49. And here's why that matters more than it might sound: this isn't an incremental tweak. This is GSK redefining who the RSV vaccine market actually serves.

The original approval was for older adults — 60 and up — where RSV hospitalization data is robust and the risk-benefit calculation is straightforward. Moving into 18 to 49 with risk factors is a different clinical conversation entirely. You're now talking about immunocompromised patients, people with chronic lung disease, cardiac conditions, diabetes with complications. These are patients whose pulmonologists and cardiologists have been waiting for prevention options.

And the timing is strategic. Moderna's mRNA RSV vaccine is in the mix. Pfizer has Abrysvo. Both are angling for market share. GSK just locked in the broadest age indication for any RSV vaccine currently approved. That's not just a label — that's a defensive moat.

Though I'd push back slightly on the moat framing. The clinical bar for these younger at-risk populations isn't necessarily higher, but the commercial uptake challenge is real. RSV vaccination in adults hasn't penetrated anywhere close to flu or COVID levels. Physicians aren't reflexively recommending it yet.

Fair. The approval opens the door — GSK still has to walk through it. But think about what this does to the sales force strategy. Every pulmonologist, every cardiologist, every transplant specialist just became a potential prescriber. The call points multiply overnight.

And from a public health standpoint, there's a population health argument here that's been hard to make before. Younger immunocompromised patients — transplant recipients on immunosuppression, people on biologics for autoimmune conditions — they've had to wait until they aged into eligibility. That gap just closed.

The question I keep coming back to is whether GSK can convert this label into uptake before competitors catch up. Moderna's platform is fast. Pfizer has commercial muscle. This is a head start, not a finish line.

Exactly right. The label is the asset. Execution is the variable.

That GSK story is about building a franchise. This next one is about trimming one. Pfizer announced they're shutting down Ignite — their R&D services unit that was specifically designed to support small biotech companies.

Ignite was supposed to be a bridge. Pfizer provides CRO-like services — protocol design, regulatory strategy, clinical operations support. Small biotechs get access to big pharma infrastructure they couldn't afford on their own. And Pfizer gets early visibility into emerging science, potential pipeline assets, relationships that could turn into deals.

In theory, it's elegant. In practice, it required Pfizer to run what amounts to a services business inside a company that's built to discover and commercialize drugs. Different muscles. Different economics.

And different priorities now. Pfizer's post-COVID restructuring has been relentless — cost cuts, pipeline prioritization, pulling resources back to programs they believe in. Ignite was a nice-to-have. It just became a have-not.

For small biotechs that were leaning on that relationship, the message is blunt: find another partner. And there aren't many big pharma companies offering this kind of support. Pfizer was one of the few actually trying it at scale.

The read-through for the broader ecosystem is worth noting. When big pharma pulls back from early-stage support, the funding gap for small biotechs widens. VCs are already selective. If the infrastructure partners disappear too, the valley of death gets deeper.

Also worth watching — Y-mAbs terminated a radiopharmaceutical trial this week. No endpoint data released, no detailed explanation. Just the termination notice.

Radioligand therapy has been riding enormous momentum since Novartis's Pluvicto success. Capital has flooded in. But Y-mAbs is a reminder that the target class isn't universally forgiving. Not every tumor type, not every construct, not every dosing strategy is going to work.

The thesis isn't broken. But the selectivity filter for investors just tightened. The next wave of radioligand players will face harder questions about differentiation.

Staying with approvals — Novartis picked up one this week that's easy to overlook but clinically meaningful. The FDA cleared Cosentyx for pediatric patients age 12 and older with moderate to severe hidradenitis suppurativa.

HS is a brutal disease. Painful abscesses, scarring, recurrence. It's stigmatizing in a way that most dermatologic conditions aren't. And it often emerges around puberty — which makes a pediatric indication genuinely important.

According to Novartis, Cosentyx is now the only IL-17A inhibitor approved for this population. They're also calling it the first differentiated mechanism in nearly a decade for pediatric HS. That's a narrow position, but it's defensible.

How does the competitive landscape look?

Thin. Adult HS has Humira — which is now off-patent and facing biosimilar pressure — plus a couple of IL-17 options. But pediatric has been genuinely underserved. Dermatologists treating adolescents with moderate-to-severe disease have had limited tools. Cosentyx fills a gap that's been open for years.

So Novartis gets exclusivity in a niche, but it's a niche that matters to the patients in it.

Precisely. And the IL-17A mechanism has established efficacy in HS — this isn't a speculative pathway. The extension into pediatrics is clinical validation, not clinical risk.

Two more regulatory items worth flagging. First, the FDA rejected Hyloris's antiviral application — not on efficacy grounds, purely manufacturing. CMC issues. It's a reminder that the quality bar at FDA remains high, and not every regulatory setback is about whether the drug works.

Manufacturing has become a recurring theme this week. We'll come back to that.

Second — and this one's important for the competitive landscape — Shanghai-based Unixell received FDA clearance to begin a U.S. cell therapy trial. BioPharma Dive described it as a first for Chinese biotech in cell therapy testing on U.S. soil.

China has invested heavily in cell and gene therapy. This is another step in that ecosystem's maturation — from domestic-only development toward FDA-grade clinical programs.

The implication is straightforward: the competitive field for advanced therapies just got more global. U.S. companies are no longer the only ones running FDA trials in these modalities. The cost structures coming out of China could pressure pricing assumptions across the space.

Looking ahead — manufacturing is emerging as the story that connects everything we've talked about this week. Gilead flagged that manufacturing scale is the key bottleneck for their Yeztugo PrEP rollout. Lenacapavir is a twice-yearly injectable with blockbuster potential in HIV prevention — but only if they can make enough of it.

Injectable long-acting formulations have different manufacturing challenges than oral. The fill-finish capacity, the cold chain logistics, the batch consistency at scale. Gilead is being transparent that this is the constraint they're working against.

And then there's the broader context. The 2026 patent cliff is looming. Multiple major products lose exclusivity this year. The revenue pressure is already showing up in how companies are allocating capital.

Lilly's $3 billion China manufacturing expansion we covered earlier this week fits that pattern. They're building capacity for the next generation of products — particularly the oral GLP-1, orforglipron — before patent expirations start hitting the P&L.

So the thread connecting Gilead, Lilly, and even the Hyloris rejection is this: in a year defined by patent cliffs and pipeline transitions, manufacturing execution may matter as much as clinical execution. The companies that can scale production for their next-generation assets are the ones that will navigate 2026 intact.

Keep an eye on the CMC headlines. They're not as exciting as Phase 3 readouts, but they're increasingly where value is won or lost.

And that is your Pharma Closeout for Friday, March 13th — GSK redefining who gets RSV protection, Novartis carving out pediatric HS, Pfizer pulling back from the biotech ecosystem, and manufacturing emerging as the throughline for 2026. A week that started with Lilly betting $3 billion on China ends with the whole industry grappling with what it takes to actually make the next generation of drugs. If someone on your team needs to be across what's moving pharma, send them this feed — and if this briefing saves you time, drop us a rating on Spotify.

Full week. Real implications. Go enjoy your weekend, and we'll be back Sunday with the Weekend Closeout to set you up for what's ahead. See you then.